EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 28, 2025--
EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development.
Unmatched Quality and Efficiency
XDel Knockout Cells outperform traditional single-guide RNA (sgRNA) CRISPR methods, delivering significantly higher on-target editing efficiency while minimizing off-target effects. With a unique multiple guide RNA design, XDel technology utilizes up to three intelligently coordinated gRNAs to create efficient and consistent fragment deletions in target genes. This approach ensures persistent protein depletion and eliminates the variability often encountered with single-guide methods.
Key Benefits of XDel Knockout Technology:
Different Formats and Cell Types to Meet Research Needs
XDel Knockout Cells are available in a variety of customizable formats, including cell pools, cell clones, and engineered cell libraries. Researchers can select from immortalized cells or induced pluripotent stem cells (iPSCs), either customer-supplied or EditCo-supplied, ensuring compatibility with diverse experimental workflows.
Driving Discovery Forward
'XDel Knockout Cells are designed to empower researchers with the confidence and reproducibility they need in guaranteed CRISPR knockouts to drive groundbreaking discoveries with ease,' said Travis Maures, CSO of EditCo Bio. 'With novel XDel technology and the freedom to easily order reliable knockout cell pools and clones across cell types, we are setting a new benchmark for CRISPR gene editing, democratizing CRISPR and making complex experiments simpler and more efficient.'
The introduction of XDel Knockout Cells is a strategic extension of EditCo's comprehensive Engineered Cell portfolio. It further solidifies the company's position as a leader in cell engineering solutions that includes precision knockout and knock-in technologies across cell types, including immortalized, iPS, and primary cell lines like T cells and fibroblasts.
To learn more about XDel Knockout Cells, visit www.editco.bio or contact EditCo at www.EditCo.bio/contact.
About EditCo Bio, Inc.
EditCo Bio is a pioneer in the development of CRISPR-engineered cell models and high-throughput gene editing solutions. Originally a spinout of Synthego, EditCo Bio leverages the expertise, technology, and partnerships that are critical for creating a novel, end-to-end CRISPR platform able to accelerate scientific discoveries. They're dedicated to building out a more accessible research toolkit to make genome engineering easier, faster, and more reliable. To learn more about EditCo Bio, visit our website at www.EditCo.bio.
Lindsey Wolf
SOURCE: EditCo Bio, Inc.
Copyright Business Wire 2025.
PUB: 01/28/2025 01:00 PM/DISC: 01/28/2025 01:00 PM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
'AI-First' Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI
CAMBRIDGE, UK--(BUSINESS WIRE)--After a wave of bold 'AI-first' announcements from major tech players, many are now scaling back. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. Share As the AI gold rush slows, a new report from Speechmatics explores what's actually working — and where the real value lies. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report zeroes in on one of the fastest-evolving areas of AI: Voice AI. Built on interviews with leaders across healthcare, compliance, media, public services, and research, it reveals a clear shift from flashy demos to embedded, operational AI — where tools assist humans, deliver measurable ROI, and quietly power core infrastructure. Report highlights include: Assistive over autonomous: The most effective deployments augment people rather than replace them. Assistive agents are driving real ROI. Multilingual as standard: Real-time code-switching is now a baseline requirement, not a bonus. Accuracy is make-or-break: With growing global concerns over AI hallucinations, precision is essential — especially in compliance-heavy environments. Voice as infrastructure: Quietly embedded tools are outperforming headline-grabbing features. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. It's being embedded into workflows that demand speed, accuracy, and trust — from noisy control rooms to multilingual contact centres. The report closes with future-looking predictions, outlining the rise of emotionally intelligent, adaptive, and natively multilingual voice systems — and offers guidance on what enterprises must prioritise next.
Business Wire
3 hours ago
- Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for . Upcoming presentation at BIO 2025 follows successful Series B funding round and encouraging data from ongoing trials The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. 'We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders,' said Stefano Portolano, CEO at Azafaros. 'With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need.' About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Business Wire
5 hours ago
- Business Wire
Western Union Appoints Vince Tallent to Drive Asia Pacific Growth and Operations
SINGAPORE--(BUSINESS WIRE)--Western Union today announced the appointment of Vince Tallent as Senior Vice President, Head of Asia Pacific. His appointment comes as the Company accelerates its strong growth momentum in the region across its digital, retail and broader ecosystem presence. Tallent brings a wealth of expertise to Western Union, having built a distinguished career within the fintech and telecommunications, media & technology (TMT) industries. He has extensive experience growing international businesses and delivering innovative service offerings. These include multi-service apps with in-app purchases, data transfer, marketplaces, card services, alternative payment methods and cutting-edge digital banking solutions across both developed and emerging markets. 'Vince's leadership and diverse experience in scaling technology-driven financial services will be invaluable as we continue to strengthen our position in Asia Pacific,' said Giovanni Angelini, Western Union's President for Europe, Middle East, Africa and Asia Pacific. 'His proven track record in driving operational excellence and business growth will help us tap into the region's dynamic market potential, expand our offerings, and deliver innovative solutions to our customers.' Tallent joins Western Union from tiqmo, an innovative fintech app in Saudi Arabia that serves customers across the Middle East and North Africa. He joined tiqmo initially as Group COO and CFO, ultimately becoming CEO in 2022. Prior to tiqmo, Tallent held senior leadership positions at top fintech and TMT companies in Asia Pacific, the Middle East, and Europe where he led transformational strategies that drove growth and innovation. 'I'm delighted to join Western Union at such a pivotal time for the company,' said Vince Tallent. 'This is an exciting opportunity to build on Western Union's growth momentum in the region by delivering customer-centric, innovative solutions that empower individuals as they send and receive money, ultimately making financial services accessible for all.' Vince Tallent holds an MBA in Advanced Finance & Corporate Strategy from Kingston University, London, where he was also awarded an Honorary Doctorate for his outstanding contributions to business, entrepreneurship, and philanthropy. He is also a Fellow of the Chartered Institute of Management Accountants (CIMA) in London. About Western Union The Western Union Company (NYSE: WU) is committed to helping people around the world who aspire to build financial futures for themselves, their loved ones and their communities. Our leading cross-border, cross-currency money movement, payments and digital financial services empower consumers, businesses, financial institutions and governments—across more than 200 countries and territories and nearly 130 currencies—to connect with billions of bank accounts, millions of digital wallets and cards, and a global footprint of hundreds of thousands of retail locations. Our goal is to offer accessible financial services that help people and communities prosper. For more information, visit
